The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Janssen; Merck; Novartis; Pfizer; Sanofi; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Heather Jacene
Honoraria - Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Consulting or Advisory Role - Advanced Accelerator Applications
Research Funding - Blue Earth Diagnostics (Inst); GTx (Inst); Siemens Healthineers (Inst)
 
Pamela J. Atherton
No Relationships to Disclose
 
Gabriela Perez Burbano
No Relationships to Disclose
 
Archana Ajmera
No Relationships to Disclose
 
Shiva Baghaie
No Relationships to Disclose
 
Janet Koball
No Relationships to Disclose
 
Tyler J. Zemla
No Relationships to Disclose
 
Ronald C. Chen
Consulting or Advisory Role - Abbvie; Accuray; Accuray; Bayer; Blue Earth Diagnostics; Genentech; Medivation/Astellas; Myovant Sciences; Pfizer
Research Funding - Accuray
 
Atish Dipankar Choudhury
Employment - LeMaitre Vascular (I)
Honoraria - Astellas Pharma; Bayer; Janssen; Journal of Clinical Pathways/Oncology Learning Network; OncLive; OncLive; OncLive
Consulting or Advisory Role - Bayer; Clovis Oncology; Dendreon; MedaCorp
Research Funding - Bayer; Janssen (Inst)
Travel, Accommodations, Expenses - Genentech
 
Joshua Michael Lang
Stock and Other Ownership Interests - Salus Discovery
Consulting or Advisory Role - 4D Pharma; Immunomedics; Janssen; Pfizer/Astellas; Sanofi; Sanofi
Research Funding - Agensys (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck Sharp & Dohme (Inst)
 
Tareq Al Baghdadi
Stock and Other Ownership Interests - Array BioPharma; AstraZeneca; Biogin; Bristol-Myers Squibb; Celgene; Epizyme; HERON; Portola Pharmaceuticals; Seagen; Spectrum Pharmaceuticals; Sunesis Pharmaceuticals; TRACON Pharma
Honoraria - Cardinal Health
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; Kite, a Gilead company; MorphoSys
Travel, Accommodations, Expenses - Abbvie/Genentech; Bristol-Myers Squibb; Cardinal Health
 
Young Kwok
No Relationships to Disclose
 
Himisha Beltran
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Blue Earth Diagnostics; Genzyme; GlaxoSmithKline; Janssen Oncology; Pfizer
Research Funding - Abbvie/Stemcentrx (Inst); Janssen (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Physicans' Education Resource; Propella Therapeutics; Sanofi; Vizuri
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday
 
Michael J. Morris
Consulting or Advisory Role - Advanced Accelerator Applications; Athenex; Bayer; Curium Pharma; Curium Pharma; Endocyte; Johnson & Johnson; ORIC Pharmaceuticals
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Janssen (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Endocyte; Fujifilm
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; IQvia; Janssen Oncology; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel